Marinus Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Marinus Pharmaceuticals
MRNS Stock  USD 0.32  0.01  3.97%   
Marinus Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Marinus Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Marinus Pharmaceuticals financial statements helps investors assess Marinus Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Marinus Pharmaceuticals' valuation are summarized below:
Gross Profit
-55.9 M
Market Capitalization
17.1 M
Enterprise Value Revenue
0.9808
Revenue
30.3 M
Earnings Share
(2.47)
There are over one hundred nineteen available fundamental ratios for Marinus Pharmaceuticals, which can be analyzed over time and compared to other ratios. All traders should check Marinus Pharmaceuticals' last-minute fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 613.4 M in 2024. Enterprise Value is likely to gain to about 602.7 M in 2024

Marinus Pharmaceuticals Total Revenue

32.54 Million

Check Marinus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Marinus Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 578.5 K, Interest Expense of 17.7 M or Selling General Administrative of 63.5 M, as well as many indicators such as Price To Sales Ratio of 17.91, Dividend Yield of 0.0 or PTB Ratio of 36.59. Marinus financial statements analysis is a perfect complement when working with Marinus Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Marinus Pharmaceuticals Correlation against competitors.
For more information on how to buy Marinus Stock please use our How to Invest in Marinus Pharmaceuticals guide.

Marinus Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets102.1 M170.9 M82.3 M
Slightly volatile
Short and Long Term Debt Total115.9 M110.4 M25.1 M
Slightly volatile
Other Current Liabilities23.2 M22.1 M7.6 M
Slightly volatile
Total Current Liabilities42.7 M40.6 M16 M
Slightly volatile
Total Stockholder Equity15.9 M16.8 M45.7 M
Slightly volatile
Property Plant And Equipment Net5.1 M4.8 M1.7 M
Slightly volatile
Current Deferred Revenue18.9 M18 M13 M
Slightly volatile
Accounts Payable2.4 M4 M2 M
Slightly volatile
Cash88.1 M120.6 M71.1 M
Slightly volatile
Non Current Assets Total7.8 M5.7 M6.2 M
Slightly volatile
Non Currrent Assets Other778 K819 K2.7 M
Slightly volatile
Cash And Short Term Investments92.1 M150.3 M74.3 M
Slightly volatile
Common Stock Total Equity35.9 K57.5 K30.2 K
Slightly volatile
Common Stock Shares Outstanding56.4 M53.7 M17.4 M
Slightly volatile
Liabilities And Stockholders Equity102.1 M170.9 M82.3 M
Slightly volatile
Other Current Assets9.2 M8.7 M2.9 M
Slightly volatile
Other Stockholder Equity618.1 M588.7 M254.2 M
Slightly volatile
Total Liabilities161.9 M154.1 M41.6 M
Slightly volatile
Property Plant And Equipment Gross6 M5.7 M2 M
Slightly volatile
Total Current Assets94.3 M165.2 M76.1 M
Slightly volatile
Short Term Debt15.3 M14.5 M4.1 M
Slightly volatile
Common Stock37.9 K55 K30.2 K
Slightly volatile
Property Plant Equipment5.1 M4.9 M1.7 M
Slightly volatile
Other Liabilities19.7 M18.7 M6.2 M
Slightly volatile
Net Tangible Assets76 M128.8 M66.1 M
Slightly volatile
Long Term Debt Total85.8 M81.7 M32.3 M
Slightly volatile
Capital Surpluse317.7 M623.8 M266.3 M
Slightly volatile
Short and Long Term Debt12.1 M11.6 M4.7 M
Very volatile
Non Current Liabilities Other745.8 K785 K4 M
Slightly volatile
Net Invested Capital81.7 M89.7 M67.2 M
Slightly volatile
Net Working Capital115.2 M124.6 M80.7 M
Slightly volatile
Capital Stock52.2 K55 K2.8 M
Pretty Stable
Warrants22.6 M25.4 M27.6 M
Slightly volatile
Capital Lease Obligations1.4 M774 K775.4 K
Slightly volatile
Net Receivables4.1 M3.8 M2.4 M
Slightly volatile

Marinus Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization578.5 K551 K219.2 K
Slightly volatile
Selling General Administrative63.5 M60.5 M18.8 M
Slightly volatile
Other Operating Expenses170.6 M162.5 M55.9 M
Slightly volatile
Research Development104.4 M99.4 M36.6 M
Slightly volatile
Total Operating Expenses168.6 M160.5 M55.5 M
Slightly volatile
Interest Income8.5 M8.1 M1.6 M
Slightly volatile
Reconciled Depreciation337.2 K508 K224.3 K
Slightly volatile

Marinus Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation16.3 M15.6 M5.9 M
Slightly volatile
Begin Period Cash Flow252.6 M240.6 M73.1 M
Slightly volatile
Depreciation578.5 K551 K191.3 K
Slightly volatile
Capital Expenditures113 K119 K651.2 K
Slightly volatile
End Period Cash Flow88.1 M120.6 M71.1 M
Slightly volatile
Issuance Of Capital Stock65.6 M90.4 M98.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio17.9118.8526237
Slightly volatile
PTB Ratio36.5934.84799.8497
Pretty Stable
Days Sales Outstanding42.5144.746273
Slightly volatile
Book Value Per Share0.30.31195.8471
Pretty Stable
Average Payables77.2 K86.9 K94.6 K
Slightly volatile
Stock Based Compensation To Revenue0.480.50222.7783
Pretty Stable
Capex To Depreciation0.210.2162.865
Pretty Stable
PB Ratio36.5934.84799.8497
Pretty Stable
Payables Turnover0.460.48311.6489
Pretty Stable
Sales General And Administrative To Revenue2.652.797.8151
Slightly volatile
Research And Ddevelopement To Revenue3.053.207218.502
Pretty Stable
Capex To Revenue0.00360.00380.129
Pretty Stable
Cash Per Share2.662.79627.6268
Pretty Stable
Days Payables Outstanding71875522.1 K
Slightly volatile
Income Quality1.020.83451.2006
Slightly volatile
Net Debt To EBITDA0.07730.08144.4363
Pretty Stable
Current Ratio3.864.06777.3923
Very volatile
Tangible Book Value Per Share0.30.31195.8471
Pretty Stable
Receivables Turnover8.578.15712.4692
Slightly volatile
Graham Number4.084.297118.7079
Pretty Stable
Shareholders Equity Per Share0.30.31195.8471
Pretty Stable
Debt To Equity6.826.49871.3608
Slightly volatile
Capex Per Share0.00210.00220.039
Pretty Stable
Graham Net Net0.00350.00375.4234
Pretty Stable
Revenue Per Share0.610.57660.194
Slightly volatile
Interest Debt Per Share1.342.34151.5301
Very volatile
Debt To Assets0.670.63750.3045
Slightly volatile
Price Book Value Ratio36.5934.84799.8497
Pretty Stable
Days Of Payables Outstanding71875522.1 K
Slightly volatile
Ebt Per Ebit1.021.08710.9409
Pretty Stable
Company Equity Multiplier10.710.19432.7662
Slightly volatile
Long Term Debt To Capitalization0.890.85030.3457
Slightly volatile
Total Debt To Capitalization0.910.86660.4077
Slightly volatile
Debt Equity Ratio6.826.49871.3608
Slightly volatile
Quick Ratio3.814.00837.4393
Very volatile
Net Income Per E B T0.830.98920.9985
Very volatile
Cash Ratio2.822.9686.9998
Very volatile
Days Of Sales Outstanding42.5144.746273
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.811.0011.0019
Slightly volatile
Price To Book Ratio36.5934.84799.8497
Pretty Stable
Fixed Asset Turnover6.86.39874.4512
Pretty Stable
Debt Ratio0.670.63750.3045
Slightly volatile
Price Sales Ratio17.9118.8526237
Slightly volatile
Asset Turnover0.190.18130.0472
Slightly volatile
Price Fair Value36.5934.84799.8497
Pretty Stable

Marinus Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap613.4 M584.2 M207.4 M
Slightly volatile

Marinus Fundamental Market Drivers

Cash And Short Term Investments150.3 M

Marinus Upcoming Events

5th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Marinus Pharmaceuticals Financial Statements

Marinus Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Marinus Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Marinus Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Marinus Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue18 M18.9 M
Total Revenue31 M32.5 M
Cost Of Revenue1.9 M1.8 M
Stock Based Compensation To Revenue 0.50  0.48 
Sales General And Administrative To Revenue 2.79  2.65 
Research And Ddevelopement To Revenue 3.21  3.05 
Revenue Per Share 0.58  0.61 
Ebit Per Revenue(4.24)(4.46)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Marinus Stock Analysis

When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY